Novartis Shareholder Demands Board Overhaul

Artisan Partners has called for a major board shake-up at Novartis following recent drug trial failures and disappointing acquisitions. The large shareholder criticized the company deal oversight after shares dropped significantly.

Xurve View
Insights:
FILE PHOTO: A view of the Novartis booth and logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. REUTERS/Mike Blake/File Photo

A major shareholder in NOVARTIS AG-REG demanded a board shake-up after back-to-back trial setbacks erased nearly $30 billion from the company's market value. David Samra, managing director at ARTISAN PARTNERS ASSET MA -A, said the Swiss drugmaker must overhaul how it oversees acquisitions following recent failures. The pressure comes as the stock suffered a record fall during the Tuesday morning session in Zurich.